ADMA Biologics Inc (ADMA)
10.72
-0.28
(-2.59%)
USD |
NASDAQ |
Jun 26, 10:33
ADMA Biologics SG&A Expense (Annual): 59.02M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 59.02M |
| December 31, 2022 | 52.46M |
| December 31, 2021 | 42.90M |
| December 31, 2020 | 35.05M |
| December 31, 2019 | 25.91M |
| December 31, 2018 | 22.50M |
| December 31, 2017 | 18.75M |
| Date | Value |
|---|---|
| December 31, 2016 | 8.495M |
| December 31, 2015 | 6.746M |
| December 31, 2014 | 4.824M |
| December 31, 2013 | 4.365M |
| December 31, 2012 | 3.142M |
| June 30, 2011 | 0.0265M |
| June 30, 2010 | 0.0205M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
25.91M
Minimum
2019
59.02M
Maximum
2023
43.07M
Average
42.90M
Median
2021
SG&A Expense (Annual) Benchmarks
| ANI Pharmaceuticals Inc | 161.70M |
| Ligand Pharmaceuticals Inc | 52.79M |
| Vanda Pharmaceuticals Inc | 112.88M |
| Johnson & Johnson | 20.11B |
| Moderna Inc | 1.549B |